Blue Eagle Lithium
High Times
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: 4toSchool, Go-Gold, Top Penny, GoldenMind
Search This Board: 
Last Post: 10/22/2018 8:41:08 PM - Followers: 782 - Board type: Free - Posts Today: 9


US. Stem Cell, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease. We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Gregory Knutson 59 Director
Kristen Comella  37 DirectorChief Scientific Officer
Sheldon T. Anderson 63 Director



About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 


    Sunrise, FL – April 10, 2017 – U.S. Stem Cell, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has received reactivation status of the MARVEL phase II/III trial.

    Following the passing of the 21st Century Cures Act, U.S. Stem Cell, Inc. has applied to the FDA for Regenerative Medicine Advanced Therapy (RMAT) Designation for the MyoCell product as part of the MARVEL trial.  Our trial had previously been placed on “Inactive Status” as patients were not actively being enrolled.  We placed a request to the FDA to reactivate the protocol and consider the therapy for RMAT designation.  We have recently heard from the FDA who has notified us that the protocol has been placed on “Reactivation Status” after reviewing details on the protocol and data collected on patients to date.  The FDA has also notified us that they are still reviewing our submission for RMAT.  Thanks to the REGROW component of the Cures Act, The FDA will grant RMAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease.  We believe that our MyoCell product meets these requirements as we have demonstrated clinical efficacy in both preclinical and clinical studies including our most recent MARVEL trial publication (review full publication here:  If RMAT designation is granted, this could expedite the approval process with the FDA.

    More information on the FDA’s new RMAT Designation can be found here:

USRM - Daily Candlesticks

SUNRISE, Fla.Jan. 8, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced world-renowned fitness expert Ben Greenfield successfully received its stromal vascular fraction treatment for erectile enhancement.  Details of the procedure and the results are featured in the January issue of Men's Healthon newsstands now. Link here!!! ----->>>>

Ben Greenfield posted (Jan 16th, 2018) video at US Stem Cell clinic in Florida

Expecting Ben Greenfield's article to be found here once written any day now...

Press Releases:

Blue Eagle Lithium
High Times
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM News: Quarterly Report (10-q) 08/08/2018 04:09:15 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 05/18/2018 04:05:16 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 05/18/2018 04:02:40 PM
USRM News: Quarterly Report (10-q) 05/09/2018 05:14:57 PM
USRM News: Small Company Offering and Sale of Securities Without Registration (d) 05/04/2018 04:37:37 PM
PlusOneCoin Top Posts
#98011   UNITED STATES vs Comella/USRM...LAWSUIT FILED..SCATHING... Hornet Driver 09/13/18 11:52:15 AM
#98009   10-Q: SEC SUBPOENA Tomas and Comella AS INDIVIDUALS.... Hornet Driver 09/13/18 11:13:44 AM
#97274   Stem Cell Center Clinics = GONE..ANOTHER Tomas SCAM... Hornet Driver 08/08/18 11:46:13 PM
#94862  Sticky Note Is this how USRM says the FDA / Gobsmacked01 05/16/18 09:43:09 PM
#85293  Sticky Note $USRM in 1 year has ~X3 Profits,~X2 revenues,~X4 GoldenMind 12/04/17 04:27:33 PM
#79439  Sticky Note BOARD WARNING: Please Read IH Geek [Dave] 09/14/17 12:53:48 PM
#98731   Soon buying pressure will pick up ( already Lonewolf1 10/22/18 11:37:01 AM
#98728   New as in August hmm not so new ceobillionaireboys 10/22/18 09:57:36 AM
#98727   NEW ATTORNEY BLOG: LOOKS GRIM FOR USRM..... Hornet Driver 10/22/18 09:23:30 AM
#98726   Not sure this will help us much but Wolfe64 10/22/18 09:00:19 AM
#98725   $USRM: $APOP news just out should-boost $USRM today makinezmoney 10/22/18 08:58:17 AM
#98723   Hence airways for advertising not airways for planes ceobillionaireboys 10/21/18 12:22:42 PM
#98722   Nope ftc protects consumers and what I meant ceobillionaireboys 10/21/18 11:52:03 AM
#98721   Quote BS LOL, "FTC protects airways so means Hornet Driver 10/21/18 11:50:19 AM
#98720   FTC protects airways so means that scam company ceobillionaireboys 10/21/18 10:46:14 AM
#98719   FTC, CRACK DOWN ON STEM CELL CLINICS..uh oh.... Hornet Driver 10/21/18 08:56:29 AM
#98715   Looks like we’re starting another pump and dump Disbelief1 10/20/18 10:41:26 PM
#98714   UNITED STATES DOJ VS USRM INJUNCTION WORD FOR WORD.... Hornet Driver 10/20/18 09:55:21 PM
#98713   Servicse revenue grew 40% last Quarter alone. We GoldenMind 10/20/18 07:09:17 PM
#98711   Up is good! Thanks for sharing! Hippycowboy 10/20/18 06:46:28 PM
#98710   We are currently in an up trend and The dead cat bouncer 10/20/18 06:17:36 PM
#98709   Sounds good to me! Hippycowboy 10/20/18 02:55:34 PM
#98707   Dollar land is a pipe dream. Will never Disbelief1 10/19/18 11:03:20 PM
#98705   Great information hornet. Further proof that this Disbelief1 10/19/18 10:55:08 PM
#98704   This stock will see D-O-L-L-A- R-S. There is nothing Lonewolf1 10/19/18 07:42:46 PM
#98702   There is nothing in your post that makes Lonewolf1 10/19/18 07:38:34 PM
#98701   FTC, NOW CRACKING DOWN ON STEM CELL CLINICS..wowza.... Hornet Driver 10/19/18 03:37:20 PM
#98700   We really need some news.. something... anything TheDDmaster 10/19/18 03:25:47 PM
#98698   Growth is key. And growth is why I GoldenMind 10/19/18 08:58:29 AM
#98697   Watch. Laat two rips 2 4...obvious thiw level Afterhoursearnings3 10/19/18 08:15:20 AM
#98696   This stock dill not see four. It’s Disbelief1 10/19/18 03:48:16 AM
#98694   Fake PhD Kristi is a criminal and a Disbelief1 10/19/18 03:42:18 AM
#98693   Great. Why don’t you sign up to let Disbelief1 10/19/18 03:37:22 AM
#98690   Article from 6 months ago. Old News! Still Jbird17 10/18/18 09:19:51 PM
#98689   Fox 4 FL: Stem Cell RIPOFF STORY...USRM IN Hornet Driver 10/18/18 09:10:27 PM
#98685   Comella "PhD"...PANAMA ON-LINE WORDPRESS "University"..LOL.... Hornet Driver 10/18/18 07:30:05 PM
#98684   I always keep a seat on this train Hippycowboy 10/18/18 05:57:56 PM
#98683   Wish I was all in USRM today! kkdman 10/18/18 05:49:15 PM
#98682   Agreed! My daughter and I had an opportunity Hippycowboy 10/18/18 05:31:08 PM
#98681   shhhhh... i want more. kaos2k 10/18/18 05:16:25 PM
#98680   Sure. A goddess of harm to patients Disbelief1 10/18/18 05:09:59 PM
#98679   Trading under .03 on paltry volume.. Smart folks Stubbornseller 10/18/18 01:14:08 PM
#98678   Pressure building below 4.....candles growing larger. Someone is Afterhoursearnings3 10/18/18 12:37:31 PM
#98677   Bid @ .0290 it's a SUB 3 CENT POS...AGAIN....LOL... Hornet Driver 10/18/18 11:06:47 AM
#98671   It has to be said, Kristin is a Godess. kaos2k 10/18/18 08:45:24 AM
#98670   We all know it's a delay tactic. They kaos2k 10/18/18 08:43:01 AM
#98669   Laughing. Parapraxis 10/18/18 03:34:31 AM
#98665   Lol. You watch. You, your pump and dump Disbelief1 10/17/18 11:25:15 PM
#98662   You have no idea how to have a Disbelief1 10/17/18 11:14:45 PM
#98661   Expertise....ahem... There is nothing in your post that makes Lonewolf1 10/17/18 08:27:58 PM
#98660   No they won’t. This is my expertises. Disbelief1 10/17/18 08:18:32 PM
#98659   Mediation date set for 2/20/19 If no agreement reached a1tellem 10/17/18 05:02:33 PM
#98658   Dollar land! Only a matter of time until $$IsEverything$$83 10/17/18 03:48:26 PM
#98657   no no don't tell them... I like the kaos2k 10/17/18 02:33:31 PM
#98655   The FDA WILL DROP. THEY GOT NOTHING BUT kaos2k 10/17/18 12:02:49 PM
#98652   WIRED Magazine: Comella/USRM ILLEGAL CANCER TREATMENTS NOW..? Hornet Driver 10/16/18 10:52:26 PM